🇺🇸 FDA
Pipeline program

5-(1-(2-[18F] fluoroethoxy))-[3-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-propyl]-5,6,7,8-tetrahydronaphthalen

Phase 2 small_molecule active

Quick answer

5-(1-(2-[18F] fluoroethoxy))-[3-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-propyl]-5,6,7,8-tetrahydronaphthalen for Alzheimers Disease, sporadic Cerebral Amyloid Angiopathy, Parkinson is a Phase 2 program (small_molecule) at Disc Medicine with 1 ClinicalTrials.gov record(s).

Program details

Company
Disc Medicine
Indication
Alzheimers Disease, sporadic Cerebral Amyloid Angiopathy, Parkinson
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials